Alkermes plc.
ALKS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001520262
In the last 90 days, Alkermes plc. insiders filed 0 open-market purchases and 8 sales; 425 institutions reported holding it in 13F filings for Q2 2026, worth $9.32B in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Alkermes plc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 8 filings
- 4 insiders, $4.24M in total
- Insiders trading
- 4
- Net value
- −$4.24M
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Alkermes plc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | 223,422 | Sep 3, 2026 | 11 |
| Hopkinson Craig C. | EVP R&D, Chief Medical Officer | 65,389 | Sep 1, 2026 | 18 |
| Nichols Christian Todd | SVP, Chief Commercial Officer | 102,193 | Aug 17, 2026 | 6 |
| Jackson Blair Curtis | President & CEO, Alkermes plc | 241,308 | Aug 7, 2026 | 6 |
| snyderman nancy lynn MD | Director | 15,395 | Aug 3, 2026 | 2 |
| Wright Christopher I | Director | 25,680 | Jun 12, 2026 | 2 |
| Parisi Samuel Joseph | VP, Finance (Interim PAO) | 7,717 | May 29, 2026 | 5 |
| McKeon Brian P | Director | 38,536 | May 22, 2026 | 1 |
| Laurencin Cato T | Director | 33,769 | May 22, 2026 | 1 |
| Lurker Nancy | Director | 18,222 | May 22, 2026 | 2 |
| Wilson Frank Anders | Director | 35,751 | May 22, 2026 | 1 |
| Cooke Shane | Director | 106,679 | May 22, 2026 | 2 |
| Gaynor Richard | Director | 35,751 | May 22, 2026 | 1 |
| Pops Richard F | Director and CEO, Alkermes plc | 1,377,740 | Mar 4, 2026 | 2 |
| Reed Joshua | SVP, Chief Financial Officer | – | Mar 4, 2026 | 2 |
| Brown Iain Michael | SVP, Chief Financial Officer | 148,196 | Feb 28, 2025 | 0 |
| Alva Emily Peterson | Director | 27,302 | Jul 1, 2024 | 0 |
| Daglio David Angelo Jr. | Director | 27,780 | Jul 1, 2024 | 0 |
| Landine Michael J | SVP, Corp Dev., Alkermes, Inc. | 281,730 | Feb 27, 2024 | 0 |
| Wysenski Nancy | Director | 20,356 | Jul 10, 2023 | 0 |
| Anstice David W | Director | 84,905 | Jun 16, 2022 | 0 |
| Dixon Wendy L | Director | 53,124 | Jun 16, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 19, 2022 (view filing) | May 17 | 2 days | Landine Michael JSVP, Corp Dev., Alkermes, Inc. | SSale | −50.0K | $29.15 | −$1.46M | −17.7%232.3K after | |
| May 12, 2022 (view filing) | May 10 | 2 days | Landine Michael JSVP, Corp Dev., Alkermes, Inc. | SSale | −25.0K | $27.22 | −$680.5K | −9.7%232.3K after | |
| May 6, 2022 (view filing) | May 5-6 | 1 day | Pops Richard FDirector and CEO, Alkermes plc | SSale | −347.3K | $27.98 | −$9.72M | −26.4%968.3K after | 3 lots |
| May 3, 2022 (view filing) | May 3 | Same day | Landine Michael JSVP, Corp Dev., Alkermes, Inc. | SSale | −25.0K | $28.62 | −$715.5K | −9.7%232.3K after | |
| May 3, 2022 (view filing) | May 2 | 1 day | Cooke ShaneDirector | SSale | −10.0K | $29.23 | −$292.3K | −10.0%90.5K after | |
| Apr 27, 2022 (view filing) | Apr 25 | 2 days | Cooke ShaneDirector | SSale | −10.0K | $27.88 | −$278.8K | −10.0%90.5K after | |
| Apr 22, 2022 (view filing) | Apr 20 | 2 days | Jackson Blair CurtisEVP, Chief Operating Officer | SSale | −50.0K | $29.61 | −$1.48M | −36.3%87.9K after | |
| Apr 19, 2022 (view filing) | Apr 18 | 1 day | Cooke ShaneDirector | SSale | −10.0K | $28.88 | −$288.8K | −10.0%90.5K after | |
| Apr 12, 2022 (view filing) | Apr 11 | 1 day | Cooke ShaneDirector | SSale | −10.0K | $29.26 | −$292.6K | −10.0%90.5K after | |
| Apr 5, 2022 (view filing) | Apr 4 | 1 day | Cooke ShaneDirector | SSale | −10.0K | $28.18 | −$281.8K | −10.0%90.5K after | |
| Mar 8, 2022 (view filing) | Mar 4 | 4 days | snyderman nancy lynn MDDirector | PPurchase | +427 | $23.43 | +$10.0K | +4.8%9.37K after | |
| Feb 24, 2022 (view filing) | Feb 23 | 1 day | Hopkinson Craig C.EVP R&D, Chief Medical Officer | SSale | −12.0K | $24.76 | −$296.7K | −40.0%18.0K after | |
| Feb 23, 2022 (view filing) | Feb 18 | 5 days | Hopkinson Craig C.EVP R&D, Chief Medical Officer | SSale | −2.31K | $25.17 | −$58.0K | −19.5%9.50K after | |
| Aug 24, 2021 (view filing) | Aug 23 | 1 day | Alva Emily PetersonDirector | PPurchase | +1.65K | $30.22 | +$49.9K | New position1.65K after | |
| Aug 20, 2021 (view filing) | Aug 19 | 1 day | Brown Iain MichaelSVP, Chief Financial Officer | SSale | −40.0K | $29.99 | −$1.20M | −48.2%43.0K after | |
| Aug 4, 2021 (view filing) | Aug 2 | 2 days | McKeon Brian PDirector | PPurchase | +10.0K | $26.43 | +$264.3K | New position10.0K after | |
| Jul 30, 2021 (view filing) | Jul 29 | 1 day | Gaffin David JosephSVP, CLO, Alkermes, Inc. | SSale | −14.0K | $26.00 | −$364.0K | −15.8%74.6K after | |
| Jul 2, 2021 (view filing) | Jul 1 | 1 day | Anstice David WDirector | SSale | −20.0K | $24.58 | −$491.6K | −21.5%73.1K after |